Indaptus Therapeutics is trading at $2.94, down 6.80%, amid broader risk-off pressure on growth stocks. - No new company-specific catalyst explaining the October 22 decline was identified; the latest reported company news was completion of a $24 million private placement. - Reuters reported pressure on growth stocks amid renewed AI-spending concerns and rising oil prices.